Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study

BACKGROUND: Fibromyalgia patients from a long-term, open-label study of milnacipran (50–200 mg/day) were eligible to participate in a 12-week, randomized, placebo-controlled withdrawal study. The withdrawal study evaluated loss of therapeutic response in patients who achieved ≥50% pain improvements...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip J, Clauw, Daniel J, Trugman, Joel M, Palmer, Robert H, Wang, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247140/
https://www.ncbi.nlm.nih.gov/pubmed/25473309
http://dx.doi.org/10.2147/JPR.S70200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247140/
https://www.ncbi.nlm.nih.gov/pubmed/25473309
http://dx.doi.org/10.2147/JPR.S70200

Ejemplares similares